Potent small molecule CCR1 antagonists.
The present manuscript details structure-activity relationship studies of lead structure 1, which led to the discovery of CCR1 antagonists >100-fold more potent than 1.
Kath
John C
JC
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. john_c_kath@groton.pfizer.com
Brissette
William H
WH
Brown
Matthew F
MF
Conklyn
Maryrose
M
DiRico
Amy P
AP
Dorff
Peter
P
Gladue
Ronald P
RP
Lillie
Brett M
BM
Lira
Paul D
PD
Mairs
Erin N
EN
Martin
William H
WH
McElroy
Eric B
EB
McGlynn
Molly A
MA
Paradis
Timothy J
TJ
Poss
Christopher S
CS
Stock
Ingrid A
IA
Tylaska
Laurie A
LA
Zheng
Deye
D
D002460:Cell Line; D006801:Humans; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
C515300:CCR1 protein, human; D054389:Receptors, CCR1; D019707:Receptors, Chemokine